Semetinib for adults with type 1 neurofibromatosis
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed diagnosis of NF1 based on standard criteria (like certain spots, freckling, or gene testing)
- You must have a solid tumor that has been biopsied and is not a malignant peripheral nerve sheath tumor
- You must have at least one tumor that can be measured on scans
- Your tumor must not involve the brain or spine, and you must be a candidate for surgery
- You must be in generally good health (able to walk around and care for yourself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called smethinib (a type of targeted therapy) for people with neurofibromatosis type 1 whose tumors have grown into the brain, spine, or other important organs and cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.